Objective: The objective of this paper is to analyze the development of China's national essential medicines list (NEML) from 1979 to 2010. These findings were then used as a basis to provide suggestions on how to improve essential medicines selection in China.
Introduction
Essential medicines (EMs) are medicines that address the priority health care needs of the population. They are selected with regards to public health relevance, evidence on efficacy and safety and comparative cost-effectiveness 1 . Establishing a national essential medicines list (NEML) is a core element to national pharmaceutical policy 2, 3 .
As the largest developing country with the population of more than 1.34 billion and medicines accounting for over 40% of total health expenditure, promoting essential medicines use in China is extremely important. China's public health facilities sell medicines for profit with a mark up of 15% 4 . Over 45% of
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The selection of essential medicines in China medicine inclusion criteria and selection procedures. We use these as a basis to provide suggestions on how to improve essential medicines selection in China.
Methodology
The literature review was performed on published peerreviewed papers on essential medicines in China. The search was performed in English and Chinese. We indentify publications [16] [17] [18] . Data from the WHO suggest that the availability of EMs was below 20% in China which is significantly lower than neighboring countries with similar economic development level 19 . 
Latest NEML and its selection
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The selection of essential medicines in China The overall managing authority called National Essential Medicines Working Group decides the new principles and criteria 22 . Medicines are listed on the basis that they should be necessary for clinical use and disease prevention and should be of high efficacy, safety and assured quality. They should be convenient to use and rationally priced. The managing authority reiterates that TCMs should be considered with same importance as western medicines. Selecting principles and criteria apply to both western medicines and TCMs. It also states that the selection should "learn from international experience" 22 .
The Ministry of Health (MOH) is responsible for selection of EMs for the latest NEML. The MOH has formed a committee which consists of a pool of experts in the field of medicine, pharmaceutical economics, pharmacy, health insurance, health management and pricing. Experts are divided into a review group and a consult group whose members are mutually exclusive. The consult group evaluates medicines and proposes their opinions on the medicines before forming candidate lists. The reviewing group votes for the candidate lists and determines the draft list. The draft list receives comments from government departments before handing to managing authority for final approval 23 .
The WHO model list and the NEML
By comparing the WHO EM list and the NEML of China, we can see some important differences. First, the quantity of included western medicines varied substantially. As a result, the diseases covered by the two lists are different. The WHO list has 358 western medicines which is 103 more than NEML. The WHO list covers some important diseases such as cancers that the NEML does not cover. The WHO list also covers more medicines within some disease, e.g. there are more medicines for diabetes in the WHO list than the NEML 24 . In the WHO list, medicines are defined using doses and dosage forms. In the NEML list medicines are only defined using dosage forms for both western and TCMs. This influences the EMs manufacturing, procurement and use. Second, medicine classification and the definition of medicines varies between the two lists. The Anatomical Therapeutic Chemical Classification (ATC-C) is used in the WHO list to classify medicines while Clinical Pharmacology Classification is used for western medicines in the NEML. This is because the NEML may need to conform to other medicines lists for social health insurance schemes. Third the WHO has selected a complementary list which presents EMs for priority diseases that need specialized diagnostic or monitoring facilities and may have lower cost-effectiveness in some circumstances 25 . The WHO has also selected two editions of essential medicines for children. Even though a group of national representatives in China urged the government to select essential medicines for children 26 , no official response has been found for this appeal. The NEML does not have complementary medicines; however, provincial selection is allowed to add medicines to complement NEML but must include every medicine in the NEML 27 . We summarize discrepancies between the two lists in Table 2 .
Discrepancies in selection
The different selection procedures of the WHO list and the NEML could have an effect on end users. The WHO's selection criteria, used as a model for countries, emphasizes evidence of medicines' safety and efficacy, cost-effectiveness and total cost of treatment, availability and stability of medicines and high priority of single-compound medicines 1 . The NEML, which is aimed at the needs of China, emphasizes similar criteria of WHO's selection with additional consideration given to the medicines needed in grass root level, local availability, affordability, priority diseases 22 .
Although it is important that China establishes its own list, the list should be made in a way that is transparent, involves all stakeholders and accountable to the population. The WHO makes its list using a presenter from the expert committee who is appointed to summarize data on comparative efficacy, safety and cost-effectiveness. The recommendation is written by the presenter and is sent to experts inside the WHO for review and is posted on the WHO website for public comments. The expert committee reviews all the information and makes final selection recommendations 28 . In China, medicines are chosen and the candidate list is made by a group of consultants. The candidate list is sent to a review group whose members vote for medicines in the candidate list. The draft list is built on the result of voting 29 . Detailed information of selection procedures is not revealed and information on the methods of selection is not disclosed.
There are also differences in the number of experts and the size of the selection committee. The expert advisory panels and committees contain 781 experts of various areas (January 2006) 30 . When selecting the WHO list, 8-12 members are chosen from expert committees for the selection of EMs, who then make the selection decision for the WHO list 28 . The expert pool for the NEML is substantially larger, containing over 3000 
Provincial selection
The central government gave authority to provincial governments to select additional medicines to complement the NEML. These complementary medicines are from the national basic health insurance and working injury medicines list, which is the medicine reimbursement list for social health insurance scheme. The reason the authority was given to the provinces is to address local need. Provincial governments cannot remove medicines already in the NEML. Provincial government can add more medicines at provincial level and publish provincial list, transfer the power of selection to municipal governments while setting upper limit or range, or the provinces may opt not to conduct provincial selection 27 . Up to the end of 2010, out of 31, 22 provinces had published their own lists, and of those, 17 provinces published provincial lists with additional western medicines and TCMs. Shandong province and Anhui province have published separate lists for urban and rural areas. In terms of numbers of medicines selected, the provincial selection of the 17 provinces ranged between 76 and 381 medicines with an average of 179.9. We summarize the provincial lists in Table 4 .
Three of the provinces have set an upper limit or range of additional medicines at provincial level and gave the authority of selection to cities. In Guangxi, the provincial government allows municipal governments to select 30% more medicines than the NEML. In Hunan province, the provincial government authorizes the municipal government to select 70-90 additional medicines. 
Economic and technical influence on provincial selection
We allocated provinces to one of three categories according to their level of Gross Domestic Product per capita. More developed provinces included more medicines than less developed provinces. The eight provinces that do not have complementary provincial selection fall in the medium developed area or least developed area with the exception of Beijing. This may reflect financial barriers. Table 5 illustrates economic influence on provincial selection. Due to insufficient human resources, poor and remote provinces may have difficulty in conducting the evidence based selection process.
Discussion
Improving selection by comparing the model list and NEML
The WHO list is meant to be a model for countries to follow but must be adapted in country to fit the needs of the population 32 . However, many national lists tend to include medicines that are not in the WHO list When updating the NEML, the F+D of medicines should be defined. When defining forms and dose for medicines, attention should be paid to medicines available on the market as EMs in China tend to have much different medicines doses and forms than other countries [17] [18] .
Increasing transparency, involvement and accountability in selection
The selection in general should be transparent, involve stakeholders and should be accountable to the population.
Transparency will help ensure that the selection is unbiased and that the medicines included meet the needs of the population.
The selection process has improved, but there is still a need to improve it further. The government should be more open about how the evidence-based selection is conducted. Criteria for selecting committee members, conflict of interests and standard operating procedures should also be provided to make the board more accountable. Opinion from the public, especially from patients should be asked for and considered during the drafting of the NEML list. Table 6 summarizes the difference in transparency and accountability in the selection of the WHO list and the NEML. 
Enhancing collaboration to maximize efficiency
The selection of NEML should fully utilize the results of evidencebased selection completed by the WHO and its partners. Using the evidence-based selection already completed by the WHO would decrease the costs of making the NEML because it would not have to do its own evidence evaluation. Within China, a cooperative network could be assembled to fully utilize existing resources and established facilities. Instead of the national and provincial governments drawing up their lists independently, they can do so cooperatively and merge some procedures which could reduce costs of making the lists for both parties. The MOH should provide technical support to provinces, especially to undeveloped provinces which might not be able to carry out evidence-based selection. Information on medicines selection should be shared among the NEML selection and provincial selection.
China covers a vast and diverse territory. Within the country, different provinces have different disease profiles and social development levels which lead to difference in selecting provincial medicines lists. We summarize this in Graph 1. It is also important to make sure that appropriate local medicines are included because the provincial lists are used in health facilities. Although the provinces can make their own lists, it is important to examine why the number of medicines on the provincial list varies. One consideration that needs to be made is that less developed provinces may have higher need for EMs.
Conclusion
The latest NEML for health facilities in grass root level is significantly improved over the past lists. The establishment of China's latest NEML has made great progress in setting appropriate targets, selection principles and criteria. The selection is more transparent and evidence-based than in the previous years. With the updated selection process, promoting NEML should be within national capacity and relevant to meet
